Literature DB >> 19083239

[Pathohistology and molecular genetic diagnostics in CUP syndrome].

C Wittekind1, L-C Horn.   

Abstract

Patients with cancers of unknown primary (CUP syndrome) represent a relatively large group of cancer patients (5-10%) in whom the histomorphological diagnosis is made from tissue from the metastasis, and the site of the primary tumour remains unclear. The incidence is variable, depending on the definition used and the intensity of the search for a primary tumour. From a biological and prognostic point of view, it is helpful to distinguish eight clinical entities of the CUP syndrome; four of these entities can be subdivided histologically. Histopathologic diagnosis should be performed using a diagnostic algorithm based on the HE morphology and supplemented by immunohistochemistry. With the use of a broad spectrum of immunohistochemical markers, many tumour entities can be diagnosed, so in most cases molecular genetic investigations are not necessary.

Entities:  

Mesh:

Year:  2009        PMID: 19083239     DOI: 10.1007/s00292-008-1117-9

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  22 in total

Review 1.  Hunting the primary: novel strategies for defining the origin of tumours.

Authors:  Jayne L Dennis; Karin A Oien
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

2.  Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992.

Authors:  A J van de Wouw; M L G Janssen-Heijnen; J W W Coebergh; H F P Hillen
Journal:  Eur J Cancer       Date:  2002-02       Impact factor: 9.162

3.  Multiclass cancer diagnosis using tumor gene expression signatures.

Authors:  S Ramaswamy; P Tamayo; R Rifkin; S Mukherjee; C H Yeang; M Angelo; C Ladd; M Reich; E Latulippe; J P Mesirov; T Poggio; W Gerald; M Loda; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

4.  Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach.

Authors:  B R DeYoung; M R Wick
Journal:  Semin Diagn Pathol       Date:  2000-08       Impact factor: 3.464

5.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

6.  Molecular classification of human carcinomas by use of gene expression signatures.

Authors:  A I Su; J B Welsh; L M Sapinoso; S G Kern; P Dimitrov; H Lapp; P G Schultz; S M Powell; C A Moskaluk; H F Frierson; G M Hampton
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

7.  Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.

Authors:  E P Allhoff; K H Proppe; C M Chapman; C W Lin; G R Prout
Journal:  J Urol       Date:  1983-02       Impact factor: 7.450

Review 8.  Undifferentiated tumor: true identity by immunohistochemistry.

Authors:  Armita Bahrami; Luan D Truong; Jae Y Ro
Journal:  Arch Pathol Lab Med       Date:  2008-03       Impact factor: 5.534

9.  Multi-platform, multi-site, microarray-based human tumor classification.

Authors:  Greg Bloom; Ivana V Yang; David Boulware; Ka Yin Kwong; Domenico Coppola; Steven Eschrich; John Quackenbush; Timothy J Yeatman
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 10.  Diagnostic and therapeutic management of cancer of an unknown primary.

Authors:  N Pavlidis; E Briasoulis; J Hainsworth; F A Greco
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

View more
  1 in total

Review 1.  [The initial CUP situation and CUP syndrome: pathological diagnostics].

Authors:  R Moll
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.